APOGEE THERAPEUTICS INC
APGENASDAQTrading Snapshot
- Day Range
- $134.61 – $137.25
- 52-Week Range
- $35.39 – $135.09
- Volume
- $3.30B
- Avg Volume
- $2.87B
- Shares Outstanding
- 61.9M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $526M
- Last Q Revenue
- $135M
- P/E Ratio
- -31.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.90
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +10.0%
Why Investors Own APGE
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APOGEE THERAPEUTICS INC
APGE
StockOtter · stockotter.spaceAbout APOGEE THERAPEUTICS INC
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
AbbVie Completes Acquisition of Apogee Therapeutics
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-l
Deutsche Bank AG Acquires New Stake in Apogee Therapeutics Inc. $APGE
Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acq
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells $737,935.00 in Stock
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $134
California State Teachers Retirement System Raises Position in Apogee Therapeutics Inc. $APGE
California State Teachers Retirement System raised its stake in shares of Apogee Therapeutics Inc. (NASDAQ: APGE) by 24.1% during the undefined quarter, according to the company in its most recent 13F filing with the Sec